Clinical Features, Use of Evidence‐Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non–ST‐Elevation Acute Coronary Syndrome. Issue 6 (30th January 2014)

• Record Type: Journal Article
• Authors: Rhee, June‐Wha; Wiviott, Stephen D.; Scirica, Benjamin M.; Gibson, C. Michael; Murphy, Sabina A.; Bonaca, Marc P.; Morrow, David A.; Mega, Jessica L.
• Is Part Of: Clinical cardiology. Volume 37:Issue 6(2014:Jun.)
• Page Start: 350
• Page End: 356
• Publication Date: 2014-01-30
• Subjects: Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.22253
• Languages: English
• ISSNs: 0160-9289

Abstract

<abstract abstract-type="main" id="clc22253-abs-0001"> <title>ABSTRACT</title> <sec id="clc22253-sec-0001" sec-type="section"> <title>Background</title> <p id="clc22253-para-0001">Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular events following acute coronary syndrome (ACS). The underlying pathobiology and optimal treatments for this population continue to be evaluated.</p> </sec> <sec id="clc22253-sec-0002" sec-type="section"> <title>Hypothesis</title> <p id="clc22253-para-0002">Patients with CKD will receive fewer evidence‐based therapies and experience high rates of adverse cardiovascular events in both the short‐ and long term.</p> </sec> <sec id="clc22253-sec-0003" sec-type="section"> <title>Methods</title> <p id="clc22253-para-0003">The MERLIN‐TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST‐Elevation Acute Coronary Syndromes‐Thrombolysis in Myocardial Infarction 36) trial randomized non–ST‐elevation ACS patients to ranolazine or placebo, with no exclusion for renal dysfunction (except dialysis). We conducted a prespecified analysis among 6543 patients based on the degree of CKD.</p> </sec> <sec id="clc22253-sec-0004" sec-type="section"> <title>Results</title> <p id="clc22253-para-0004">Patients with worse renal function were older with more comorbidities (<italic>P</italic> < 0.0001 for each). They were less likely to receive evidence‐based cardiovascular medicines (<italic>P</italic> < 0.04 for each). Rates of an early invasive management strategy varied based on renal function; however, among patients with the highest TIMI risk scores, the rates of an early invasive management strategy were similar regardless of glomerular filtration rate (GFR) (<italic>P</italic><sub>interaction</sub> = 0.005). Lower GFR was associated with increased rates of cardiovascular disease or myocardial infarction in the short and long term, even after adjustment (GFR <30 vs ≥90 mL/min/1.73 m<sup>2</sup>; hazard ratio [HR]: 3.24 [95% confidence interval {CI}: 1.26‐8.38] through 7 days and HR: 2.12 [95% CI: 1.33‐3.39] through 1 year). The effect of ranolazine vs placebo on clinical outcomes was similar among those with and without CKD (<italic>P</italic><sub>interaction</sub> = not significant).</p> </sec> <sec id="clc22253-sec-0005" sec-type="section"> <title>Conclusions</title> <p id="clc22253-para-0005">Following ACS, patients with renal dysfunction had more cardiovascular risk factors but were less likely to receive evidence‐based medical therapies. A strong graded, independent relationship between the degree of CKD and poor clinical outcomes was observed over time. Continued efforts to optimize ACS treatment strategies in patients with CKD are warranted.</p> </sec> </abstract>